http://www.acc.org/Feed?clinicalTopicID=58616d42-1fda-49eb-a3ed-40ba0d5d99c0 Clinical Topic Feed: Chronic Angina en /Latest-in-Cardiology/Articles/2026/09/16/18/36/ACC-Latin-America New science focused on health disparities, cardiovascular risk factors and opportunities to improve patient outcomes will be among the topics as experts and cardiovascular clinicians from around Latin America and the U.S. come together at ACC Latin America 2026, in Medellín, Colombia, from Sept. 17 to Sept. 19. 1789646400000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/09/13/47/eagles-eye-view-09sep2026 In this week’s View, Dr. Eagle looks at some of the important trials presented at this year’s European Society of Cardiology (ESC) Congress. 1788961680000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-nature-esc-2026 Compared with conventional PCI alone, stent-retriever thrombectomy followed by PCI was associated with reduced infarct size in patients with large thrombus burden undergoing primary PCI less than eight hours from symptom onset, based on findings from the NATURE Superiority study presented at ESC Congress 2026 and simultaneously published in JACC. 1788016800000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-11am-combo-ccc-esc-2026 Researchers presenting findings from the AIR-STEMI trial at ESC Congress 2026 said a strategy of complete coronary artery revascularization guided by functional coronary angiography resulted in a lower risk of death, myocardial infarction (MI), cerebrovascular accident, or ischemia-driven revascularization in patients with STEMI and multivessel coronary artery disease compared with conventional angiography. 1788016560000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-6am-combo-interventional-esc-2026 Interventional science was the focus of a Hot Line Session at ESC Congress 2026, with studies shedding light on milvexian with antiplatelet therapy following an acute coronary event; aspirin omission at the time of primary PCI in STEMI; switching from ticagrelor to prasugrel following PCI in patients with acute coronary syndrome (ACS); clopidogrel vs. extended DAPT after high-risk PCI; and potent antiplatelet therapy in patients with atrial fibrillation (AFib) following myocardial infarction (MI). 1788005340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-jacc-journals-esc-2026 Several abstracts and e-posters presented at ESC Congress 2026 and simultaneously published across the JACC family of journals highlight the expanding role of precision medicine, novel therapeutics, and advanced risk stratification across cardiovascular care. 1788002340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/fri-viva-esc-2026 Vericiguat did not improve peripheral vasodilator function or anginal symptoms in patients with angina and no obstructive coronary arteries (ANOCA) and with epicardial and/or microvascular vasospasm. 1787914680000 Articles and Stories https://www.jacc.org/doi/10.1016/j.jacc.2026.07.025 1787913000000 Guidelines /Latest-in-Cardiology/Articles/2026/08/03/15/28/Cardiotoxicity-Risk Immune checkpoint inhibitors (ICIs) are revolutionary oncologic therapies used frontline in several malignant neoplasms, including non–small cell lung cancer, melanoma, renal cell carcinoma, bladder cancer, and colorectal cancer. 1785780720000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/ORBITA-Analysis Patients with lower microvascular resistance (MVR) saw greater placebo-controlled benefit from PCI, according to a retrospective analysis of the ORBITA trial published April 29 in JACC: Cardiovascular Interventions. 1778087340000 Articles and Stories